Context: Primary aldosteronism (PA) represents the most frequent form of endocrine hypertension. Hyperaldosteronism and hypercortisolism both induce excessive left ventricular hypertrophy (LVH) compared with matched essential hypertensives. In recent studies frequent cosecretion of cortisol and aldosterone has been reported in patients with PA.
P rimary aldosteronism (PA) is the most frequent cause of endocrine hypertension, affecting ;5% to 10% of patients with elevated blood pressure (1) . PA was first described in 1955 by Jerome W. Conn (2) and characterized in its classical form as hypertension, hypokalemia, and alkalosis. Patients with bilateral adrenal hyperplasia (BAH), the most common subtype, require lifelong treatment with a mineralocorticoid receptor (MR) antagonist (MRA), whereas patients with unilateral aldosterone-producing adenoma (APA) can be cured by adrenalectomy (ADX). Prolonged exposure to elevated aldosterone concentrations causes cardiac and renal damage independently of blood pressure (3) . These changes may have an adverse impact on clinical outcome.
One of the targets of aldosterone action are cardiomyocytes that express MRs (4) . Indeed, MR activation has been shown to induce myocardial damage (3), including diffuse myocardial fibrosis, left ventricular (LV) hypertrophy (LVH), and LV dilatation (4) . In echocardiographic studies, LVH was more frequent and more progressive in patients with PA in comparison with matched essential hypertensives (5) . Likewise, a number of studies have highlighted an increased risk of stroke, myocardial infarction, and atrial fibrillation in patients with PA (6, 7) . LVH itself is one of the most important predictors for major cardiac events, and mortality and is associated with an increased risk of arrhythmia, myocardial infection, and stroke (8) .
In a recent study, we identified cortisol cosecretion as a key feature of PA (9) associated with an adverse metabolic risk phenotype, providing a logical explanation for important comorbidities observed in patients with PA more aligned with the effects of glucocorticoid rather than mineralocorticoid excess, such as insulin resistance and type 2 diabetes (10-13), and osteoporosis (14) . Interestingly, pronounced LVH has also been described in patients with Cushing syndrome (CS), who are also afflicted by arterial hypertension, impaired glucose tolerance, and serum electrolyte imbalance (15, 16) . High cortisol levels in patients with CS are associated with an increased mortality rate due to cardiovascular complications (17) .
Therefore, we hypothesized that cortisol cosecretion observed in PA might have additional adverse effects on cardiac function and cardiovascular outcome in patients with PA. Thus, our aim was to investigate the impact of increased cortisol secretion on echocardiographic findings in patients with APA or BAH.
Methods

Patients
During 2008 and 2013 we consecutively enrolled 181 patients with PA at the Munich center of the German Conn's registry. In 136 patients a urinary steroid metabolite excretion in 24-hour urine was performed and of those 136, 73 patients with either APA (n = 45) or BAH (n = 28) attended follow-up and had a technically accurate echocardiography examination, which represents the cohort included in this study. Analysis of urinary steroid metabolite excretion and echocardiography data represented post hoc analyses. All patients gave written informed consent, and the protocol of the German Conn's registry was approved by the Ethics Committee of the University of Munich. At each visit, patients underwent standardized clinical phenotyping, including collection of anthropometric data and clinical characteristics such as duration of hypertension and current medication.
The diagnostic procedures were performed according to the Endocrine Society Practice Guidelines (18, 19) . In short, PA was diagnosed by an elevated plasma aldosterone-to-renin ratio (cut-off 10.0 ng/mU, sitting position) and an abnormal confirmatory test (e.g., salt loading test, captopril challenge test). Antihypertensive medication was stopped (n = 5) whenever possible prior to testing. Otherwise it was replaced by a1-adrenergic receptor (doxazosin) or calcium-channel blockers (verapamil) (n = 68). Subtype differentiation between unilateral and bilateral disease was based on adrenal vein sampling. In the case of APA, only patients who underwent ADX were included in the analysis. Patients with BAH were treated with MRA. In most patients, spironolactone was used at a dose of 25 to 50 mg/d. All patients were re-evaluated 1 year after treatment in a standardized fashion.
Laboratory analysis
Blood samples were drawn in a fasting state in sitting position at 8:00 AM. Plasma aldosterone concentration was measured using the radioimmunoassay "aldosterone Coat-aCount" (Biermann DPC). Active renin concentration was measured by the Liaison chemiluminescence assay (Diasorin). All other analyses were performed in our central laboratory using standard methods. To determine urinary steroid excretion, the patients conducted a 24-hour urine collection. Subsequently, gas chromatography-mass spectrometry in selected-ion-monitoring analysis mode was performed to determine the urinary steroid metabolite excretion as described previously (9) , allowing the quantification of 40 different steroid metabolites, including 3a,5b-tetrahydroaldosterone (THAldo), the major mineralocorticoid metabolite. Total glucocorticoid excretion was calculated as the sum of quantified metabolites of cortisol and cortisone, comprising tetrahydrocortisol, 5a-tetrahydrocortisol, tetrahydrocortisone, a-cortol, b-cortol, a-cortolone, b-cortolone, 6b-hydroxycortisol, and urinary cortisol and cortisone (9) .
Cardiac ultrasound examination
Comprehensive echocardiographic examination was conducted by experienced sonographers from the Department of Internal Medicine I (cardiology) from the Ludwig-MaximiliansUniversität München. The sonographers were blinded with regard to diagnosis and clinical details. Commercially available high-quality ultrasound systems were used (GE Health Care Vivid 7, Philips iE 33). The patients were lying down in the left lateral decubitus position. Echocardiography included twodimensional, M-mode, and Doppler ultrasound recordings. Images were obtained in the parasternal (long and short axis) and apical views. The LV internal dimension (LVID), interventricular septum (IVS), posterior wall thickness (PWT), and left atrial dimension in diastole were measured via the parasternal long axis view. Echocardiographic parameters were measured according to the recommendation of the American Society of Echocardiography (20, 21) . Echocardiography-based LV mass (LVM) estimation is generally calculated as the difference between epicardium delimited volume and LV chamber volume multiplied by an estimate of myocardial density (22) (23, 24) . Obesity is independently associated to LVH (25) . Because of higher average values of body mass index (BMI) in our study cohort, LVH was determined as the LVM index (LVMI). LVM was indexed by height 2.7 to obtain LVMI. By using the LVMI we minimized the interference of obesity in LVM estimation (26) . LVH was prospectively defined as a value of LVMI $50 g/m 2.7 in males and $47 g/m 2.7 in females (27) . Relative wall thickness (RWT) was calculated according to the following equation: RWT= (IVSd + PWT)/LVIDd. LVH was separated in concentric hypertrophy with RWT $0.42 and eccentric hypertrophy with RWT ,0.42 (21) . Normal LVMI values and RWT values $0.42 were defined as concentric remodeling (28) .
Statistical analysis
All values are expressed as median and 25th and 75th percentiles unless mentioned otherwise. Data between groups were compared using a Mann-Whitney U test.
Within-group changes from baseline to follow-up were calculated by a Wilcoxon signed-rank test. Spearman rank order was used to perform bivariate correlation analysis. Stepwise multiple regression analysis was used for multivariate analysis. Two-tailed probability values of ,5% were considered to be statistically significant. Statistical analysis was performed using standard statistical software (SPSS 23, IBM).
Results
Patient characteristics
Clinical characteristics of the total cohort of 73 patients with PA are shown in Table 1 , and the comparison of APA and BAH subgroups is shown in Table 2 . APA and BAH were diagnosed in 45 and 28 patients, respectively. As expected, at diagnosis, patients with APA had higher plasma aldosterone concentration (P = 0.001), higher urinary THAldo concentrations (P = 0.001), lower potassium levels (P , 0.001), and more pronounced renal impairment according to glomerular filtration rate (P = 0.043). Total glucocorticoid excretion did not differ between groups (P = 0.184).
Patient characteristics 1 year after initiation of treatment (MRA treatment in BAH, ADX in APA) are listed in Tables 1 and 2 . Systolic and diastolic blood pressure and serum potassium levels normalized in both subgroups. As expected, defined daily doses (DDDs) of antihypertensive medication decreased significantly in the APA group, whereas in the BAH group there was only a trend toward lower DDDs. BMI remained stable in both groups and both groups had a decline in renal function. Triglyceride levels increased significantly in both groups, whereas highdensity lipoprotein cholesterol levels decreased only in the BAH group (P = 0.006). Pro B-type natriuretic peptide, a potential indicator of cardiac preload, improved in both groups. The decline was not due to optimized treatment of heart failure. In fact, DDDs of ACE inhibitors/angiotensin II receptor blockers (1.4 vs 1.1; P = 0.002), b blockers (0.4 vs 0.2; P = 0.001), and diuretics (0.4 vs 0.2; P , 0.001) have decreased significantly at follow-up.
Echocardiographic findings in patients with unilateral aldosteronism and bilateral hyperplasia Table 3 summarizes echocardiographic geometric characteristics in patients with APA and BAH. LVMI was elevated, the IVS was thickened and the left atrium was enlarged in both groups at baseline. The overall prevalence of LVH was 85% before initiation of treatment, compared with 66% at follow-up. There was a shift from eccentric and concentric hypertrophy toward normal LV geometry (Supplemental Table 1 ). As expected, LVMI improved in both APA (P , 0.001) and BAH (P = 0.024) patients with treatment (Fig. 1) . The reduction of LVMI (ΔLVMI) was numerically greater in patients with APA with a significant decrease of LVIDd (P , 0.001), PWTd (P = 0.020), and IVSd (P = 0.001). In patients with BAH only LVIDd (P = 0.001) improved significantly. d Owing to incomplete data, the calculations for 24-h SBP and 24-h DBP (APA, n=35; BAH, n = 22), HDL-C, LDL-C, triglycerides, and total cholesterol (APA, n = 43, BAH, n = 27) were performed with a reduced number of patients as listed in brackets. e Data set of 39 patients with complete follow-up data.
f Data set of five patients with complete follow-up data.
THAldo, total glucocorticoid excretion, urinary sodium excretion, and LV structure As reported previously (9), both THAldo excretion and total glucocorticoid excretion were increased in patients with PA (Table 1 ). In univariate analysis THAldo (P = 0.024), urinary sodium excretion (P = 0.044), and total glucocorticoid excretion (P = 0.018) correlated with LVMI at time of diagnosis (Supplemental Figs. 1 and 2 ). In contrast, the relative changes in LVMI in response to treatment (ΔLVMI) correlated with total glucocorticoid excretion (P = 0.042), but not with THAldo (P = 0.776) or with urinary sodium excretion (P = 0.214) (Supplemental Figs. 3 and 4) . Moreover, when arbitrarily dividing patients with PA into low and high steroid secretors, according to whether their THAldo and total glucocorticoid excretions were below or above the median, high total glucocorticoid excretion, but not THAldo, predicted a reduction in LVMI (Fig. 2) . Similarly, in multivariate analyses, total glucocorticoid excretion and 24-hour systolic blood pressure were strong predictors of LV geometry changes, whereas THAldo did not have a significant effect in this model (Table 4 ). One year after treatment we could detect a significant decrease of total glucocorticoid excretion in patients with APA. In accordance with our findings in patients with APA with complete biochemical remission, a higher decrease in total glucocorticoid excretion was followed by a more distinct reduction of LVMI at follow-up (r 2 = 0.138, P = 0.023).
Discussion
To our knowledge, this is the first study to evaluate the impact of glucocorticoid cosecretion on LVH in patients with PA. PA is characterized by increased aldosterone secretion, but in recent years a relevant cortisol cosecretion has been recognized in several case reports and small case series (29) (30) (31) (32) . We have recently reported that increased secretion of glucocorticoids is a major biochemical feature in a large proportion of patients with PA, whereas clinically overt signs of CS are rare (9) . We identified cortisol cosecretion in a substantial percentage of patients with APA and BAH and reported its association with parameters of the metabolic syndrome, such as BMI, HOMA-IR, and plasma lipids. Moreover, we found that after unilateral ADX, glucocorticoid secretion normalized, followed by postoperative tertiary adrenal insufficiency in one third of patients. Based on this observation, we wondered whether total glucocorticoid excretion might also impact the cardiac phenotype in PA.
Previous echocardiographic evaluations have already demonstrated excess LVM and more frequent LVH in patients with PA (5, 33, 34) . Our patients with APA and BAH frequently had LVH according to the LVMI; the most common LV adaptation was eccentric hypertrophy. It has been described before that high plasma aldosterone concentration results in eccentric changes in LV geometry (33, 35) and that LVM is reduced by either MRA or ADX in patients with PA (36) (37) (38) (39) . A meta-analysis of four studies with an average follow-up of 4 years reported comparable effects for both treatment strategies (40) . In line with this literature, our patients responded to Abbreviations: LAd, left atrial internal dimension in diastole; n.s., no significant results; SBP, systolic blood pressure; TGE, total glucocorticoid excretion. a Significant difference. Correlation analysis was performed using Spearman's rank order test and stepwise multiple regression analysis.
treatment with a significant reduction in LVMI and an increase in the percentage of normal LV geometry. At diagnosis, LVMI in the APA group was higher than in the BAH group. At follow-up, our patients with APA showed a trend toward a more distinct reduction in LVMI compared with patients with BAH without reaching statistical significance. Inhibition of MRmediated aldosterone effects by specific medical treatment is an explanation for the comparable effects of MRA and ADX in LVM reduction. Our findings mirror previous studies reporting that the response of LVM reduction in adrenalectomized patients with PA could occur earlier than in patients with PA treated with MRA (36) . Persistent hyperaldosteronemia with possible persistence of nongenomic effects of aldosterone has been proposed to potentially explain why MRA treatment takes longer to show comparable effects than surgery (41) . The results of our study suppose an impact of cortisol cosecretion on LVH and LV geometry. Total glucocorticoid excretion was positively correlated with baseline LVMI and ΔLVMI at follow-up. Therefore, patients with higher total glucocorticoid excretion showed higher decreases in LVMI after 1 year of treatment. In line with these findings, the decrease of glucocorticoid excretion correlated with the improvement of LVMI in our patients with APA with biochemical remission.
Chronic cortisol hypersecretion, for example, in patients with CS, is known to cause, among others, truncal obesity, arterial hypertension, impaired glucose tolerance, and dyslipidemia (42) . However, also a variety of alterations in cardiac structure and function have been reported, including increased LVM, increased interventricular septum thickness, and concentric hypertrophy or remodeling (15, 16, 43, 44) . CS is known to be associated with elevated cardiovascular morbidity and mortality (45) . Cardiac dysfunction itself represents one of the most important cardiovascular complications affecting mortality. The two major forms of cardiac dysfunction in CS are cardiac hypertrophy and congestive heart failure (46, 47) . It is thought that the main cortisol effects leading to LVH are hypertension, potentiation of noradrenalin and angiotensin II responsiveness of the cardiomyocytes, and cardiomyocyte proliferation and hypertrophy (48) . MRs have similar affinity for aldosterone and cortisol. Glucocorticoid excess impairs conversion of cortisol to its MR-inactive cortisone by 11b-hydroxysteroid dehydrogenase type 2 in classical aldosterone target issues as the distal nephron, leading to glucocorticoid-mediated mineralocorticoid effects (49, 50) . In the cardiomyocytes, 11b-hydroxysteroid dehydrogenase type 2 is not expressed at relevant levels. Therefore, in physiologic circumstances the MR in cardiomyocytes is mostly occupied by cortisol, which circulates in much higher concentrations than aldosterone. In the event of cardiac tissue damage, cortisol acts as an MR agonist as shown by Mihailidou et al. (49) in ischemia/reperfusion studies in rat heart Langendorff preparations. This effect can be blocked by spironolactone but not by the glucocorticoid/progesterone antagonist RU486. However, the abnormalities in LV structure and function have been reported to ameliorate (44) or even to be reversible upon normalization of glucocorticoid excess (51) .
Therefore, treatment with ADX or MRA should both be effective against the MR-mediated effects of glucocorticoid excess on myocardial tissue. To our knowledge, no glucocorticoid-dependent MR-mediated effects on lipid and glucose metabolism have been reported so far. Therefore, MRA treatment could be inferior in this regard when increased glucocorticoid secretion in BAH remains unblocked during MRA treatment in glucocorticoid target organs, such as the endocrine pancreas, abdominal fat tissue, and the liver. In the current study, however, the improvement of glucose metabolism following ADX was minimal, but a clinical relevant improvement in glucose homeostasis has been shown previously in several cohorts (52) .
We acknowledge the limitation that steroid metabolite analysis and echocardiography were post hoc investigations and that our study was neither powered nor planned to examine differences between the two treatment strategies of PA, ADX, and MRA treatment. However, following 1 year of MRA treatment, 54% of our patients with BAH still had concentric remodeling or concentric hypertrophy as compared with 42% in patients with APA. Therefore, this finding might be explained by ongoing glucocorticoid effects in patients with BAH or inadequate MRA dosage. Unfortunately, we have only limited data for follow-up of urinary glucocorticoid excretion in patients with BAH. Additionally, 1 year of follow-up might be too short to detect full treatment effects of MRA treatment. Therefore, additional studies are required to address this issue.
It is known that patients with essential hypertension obtain LVM reduction by treatment with either ACE inhibitor or MRA and that a combination has an additive effect (53) . Blood pressure levels and antihypertensive medication according to DDDs were reduced in both groups 1 year after start of treatment. Although we detected comparable effects on 24-hour blood pressure levels, the DDDs showed numerically a greater reduction in adrenalectomized patients with APA. A contributing factor can be the rather low dose of spironolactone of an average of 42 mg/d, in accordance with Endocrine Society Practice Guidelines, which can be explained by clinical side effects including gynecomastia preventing further dose escalation. Similar to previous studies, most of the patients after ADX (58%) still needed antihypertensives because of residual hypertension (36, 54) .
The strengths of our study include the prospective standardized collection of all data and biomaterial within the context of the German Conn's registry, the homogeneously characterized study population, and the subtyping of all patients by adrenal vein sampling. A major limitation of the study is the very limited follow-up data for urinary steroid excretion (n = 5) for patients with BAH. Another limitation is the examination of LV geometry by echocardiography. The main limitation of this technique is an inappropriate acoustic window, limiting patient inclusion to suitable candidates. Second, LV parameters for estimation of LVM were generated by M-mode measurement. This is less accurate compared with real-time three-dimensional echocardiography or three-dimensional imaging by MRI (55) . Third, echocardiographic examinations in this study were performed by different experienced investigators, which could have had an influence on wall thicknesses estimation and therefore LVM and LVMI estimation. However, the investigators were blinded with regard to the underlying cause of disease, which we consider a strength of the study approach.
Conclusions
In this study, we investigated the effects of increased glucocorticoid secretion in 73 patients with PA (45 with APA, 28 with BAH) on cardiac geometry. Our data show that total glucocorticoid excretion is associated with LVH independent of mineralocorticoid excess. Moreover, high total glucocorticoid excretion, but not THAldo, predicted the ΔLVMI after ADX in patients with APA. In summary, our data suggest a relevant role of glucocorticoid secretion in PA on LV geometry, pointing out the relevance of cortisol cosecretion in the context of PA.
